News

“This is very important data that further support Glumetza as a potential first line choice for controlling diabetes,” said Dr Bret Berner, vice president, product development and chief

Galapagos and GSK, through its recently established Center of Excellence for External Drug Discovery (CEEDD), will collaborate to deliver disease modifying drugs with clinical proof of concept to

Contrave and a companion clinical program Excalia are rationally formulated, proprietary combinations of marketed CNS products. They are based on approaches to the treatment of obesity that apply

The results are from a phase Ia trial evaluating the effect of bavituximab (formerly known as Tarvacin) on viral RNA serum titers when administered as single-dose monotherapy to

In addition, a shift in the non-inferiority margin may also be justified if the safety profile of Xyotax (paclitaxel poliglumex) is superior to comparators in terms of serious

Ankylosing spondylitis (AS) is a chronic disease of the axial skeleton and large peripheral joints that causes inflammatory back pain and stiffness, but is also associated with other

The funds will be used to complete preclinical development of the vaccine and file an investigational new drug application (IND) with the FDA, which would allow initiation of

Celltrion will perform bioprocess development, scale-up, and cGMP manufacturing and provide all clinical materials to support toxicology studies as well as phase I and phase II US clinical

The open label, single-agent study will be conducted at two centers with well known expertise in developing new oncology drugs: the Barbara Ann Karmanos Cancer Institute in Detroit,